<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20191106045356N16</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-01-25</date_registration>
      <primary_sponsor>Yazd University of Medical Sciences</primary_sponsor>
      <public_title>The effect of fluconazole lozenge on oral candidiasis</public_title>
      <acronym></acronym>
      <scientific_title>The effect of fluconazole lozenge on oral candidiasis in immunocompromised patients: an experimental study and a randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-12-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67122</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients who meet the inclusion criteria receive one of the drugs labeled A or B by a simple randomization method based on the random number function (RAND), of Excel software.
Intervention with each of these drugs four times a day and
It is done for 7 days. On the 1st, 3rd, 7th, and 14th days from the beginning of the intervention, cotton sensation in the mouth, loss of taste, and pain during eating and swallowing are checked, Blinding description: Both placebo lozenges and placebo drops are prepared and placed next to lozenges containing fluconazole and nystatin drops in coded uniform containers. Patients of both study groups receive both lozenges and drops, one of which contains medicine and the other placebo. The prescribing phusician, the patient, and the data analyzer are not aware of their content.</study_design>
      <phase>3</phase>
      <hc_freetext>Oral candidiasis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Including 25 patients hospitalized in Yazd hospitals and undergoing cancer chemotherapy, who were diagnosed with oral candidiasis and met the inclusion criteria, and were randomly selected based on the RND function of Excel software. Patients in the fluconazole group use lozenges containing 20 mg of fluconazole orally 4 times a day on days 1 to 10. In this research, fluconazole lozenges are prepared using fluconazole powder purchased from Amin Pharmaceutical Company, which has a license from the Food and Drug Organization of Iran. At the beginning of the treatment and after every 2 days until 10 days, the condition of oral candidiasis lesions in terms of the total area of ​​the lesions (score 0 to 4), intervention of cotton sensation in the mouth (score 0 to 4), loss of taste, (score 0 to 4) and the number of lesions are evaluated. Intervention 2: Control group: Including 25 patients hospitalized in Yazd hospitals and undergoing cancer chemotherapy, who were diagnosed with oral candidiasis and met the inclusion criteria, and were randomly selected based on the RND function of Excel software. Nystatin group patients use 20 drops of nystatin orally 4 times a day on days 1 to 10. In this study, Nystatin drops are obtained from Emad Pharmaceutical Company, which has a license from the Food and Drug Organization of Iran. At the beginning of the treatment and after every 2 days until 10 days, the condition of oral candidiasis lesions in terms of the total area of the lesions (score 0 to 4), intervention of cotton sensation in the mouth (score 0 to 4), loss of taste, (score 0 to 4) and the number of lesions are evaluated.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Mohsen Zabihi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Alem sq.</address>
        <city>yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8916774520</zip>
        <telephone>+98 35 3820 3865</telephone>
        <email>mzabihi100@gmail.com</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Mohsen Zabihi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Alem sq.</address>
        <city>yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8916774520</zip>
        <telephone>+98 35 3820 3865</telephone>
        <email>mzabihi100@gmail.com</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The patient is undergoing cancer chemotherapy in Yazd hospitals.
The woman should not be pregnant or lactating.
Willingness to participate in the study and complete the informed consent form
Age 18 to 70 years</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>The occurrence of an allergic reaction to fluconazole
Aggravation of the disease and the need for drug intervention to control the disease
Non-cooperation in the use of medication</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>B37.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Candidal stomatitis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Including 25 patients hospitalized in Yazd hospitals and undergoing cancer chemotherapy, who were diagnosed with oral candidiasis and met the inclusion criteria, and were randomly selected based on the RND function of Excel software. Patients in the fluconazole group use lozenges containing 20 mg of fluconazole orally 4 times a day on days 1 to 10. In this research, fluconazole lozenges are prepared using fluconazole powder purchased from Amin Pharmaceutical Company, which has a license from the Food and Drug Organization of Iran. At the beginning of the treatment and after every 2 days until 10 days, the condition of oral candidiasis lesions in terms of the total area of ​​the lesions (score 0 to 4), intervention of cotton sensation in the mouth (score 0 to 4), loss of taste, (score 0 to 4) and the number of lesions are evaluated.</i_keyword>
      <i_keyword>Control group: Including 25 patients hospitalized in Yazd hospitals and undergoing cancer chemotherapy, who were diagnosed with oral candidiasis and met the inclusion criteria, and were randomly selected based on the RND function of Excel software. Nystatin group patients use 20 drops of nystatin orally 4 times a day on days 1 to 10. In this study, Nystatin drops are obtained from Emad Pharmaceutical Company, which has a license from the Food and Drug Organization of Iran. At the beginning of the treatment and after every 2 days until 10 days, the condition of oral candidiasis lesions in terms of the total area of the lesions (score 0 to 4), intervention of cotton sensation in the mouth (score 0 to 4), loss of taste, (score 0 to 4) and the number of lesions are evaluated.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Total area of oral candidiasis lesions. Timepoint: At the beginning of the treatment and after every 2 days until 10 days, the condition of oral candidiasis lesions is evaluated in terms of the total area of the lesions. Method of measurement: Determining the total area of oral candidiasis lesions through Fiji software.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Cotton feeling in the mouth. Timepoint: the beginning of the treatment and after every 2 days up to 10 days, the condition of oral candidiasis lesions is evaluated in terms of the feeling of cotton in the mouth (score 0 to 4). Method of measurement: Scoring the feeling of cotton in the mouth using a questionnaire.</sec_outcome>
      <sec_outcome>Decreased taste. Timepoint: At the beginning of treatment and after every 2 days until 10 days, the condition of oral candidiasis lesions is evaluated in terms of taste loss (score 0 to 4). Method of measurement: Scoring of taste reduction using a questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Yazd University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-10-27</approval_date>
        <contact_name>Ethics committee of Shahid Sadoughi University of Medical Sciences</contact_name>
        <contact_address>Alem sq. yazd Yazd Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
